Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

What is calcitonin gene-related peptide (CGRP)?

CGRP is a protein that helps control blood vessel expansion. It has functions all over the body but is of particular interest to people seeking treatment for migraine. Some migraine medications called CGRP monoclonal antibodies (mAbs) block CGRP due to its dir

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

CGRP is a protein that helps control blood vessel expansion. It has functions all over the body but is of particular interest to people seeking treatment for migraine.

Some migraine medications called CGRP monoclonal antibodies (mAbs) block CGRP due to its direct links to headache activity. These can help prevent migraine attacks. CGRP mAbs are the only preventive medications specifically for migraine.

This article discusses CGRP and how mAbs work to help prevent migraine symptoms.

Headache and migraine resources

To discover more evidence-based information and resources for headaches and migraine, visit our dedicated hub.

CGRP is a protein that occurs throughout the body. It has different actions and effects depending on its location.

CGRP has a range of important functions. For example, a 2018 review suggests it is crucial for:

  • expanding blood vessels
  • managing blood pressure
  • reducing a person’s risk of stroke and heart disease

However, in the brain, CGRP links to the feeling of pain and how the tissues and blood vessels react. It plays an important role in migraine pain.

For this reason, researchers have developed

Monoclonal antibodies (mAbs) are a type of synthetic medication that act like cells in the immune system. Antibodies are proteins in the immune system that

Researchers make antibodies in a lab and tailor them to a specific antigen. They then produce copies of the antibody, which becomes a mAb.

CGRP antagonists are a type of mAb that targets CGRP. A

Erenumab (Aimovig)

This was the

People can inject Aimovig themselves using a prefilled syringe or autoinjector. It is available in 70 milligrams (mg) and 140 mg.

Fremanezumab (Ajovy)

Ajovy

People can either receive Ajovy through monthly injections of 225 mg or a 675 mg dose every 3 months that consists of three injections, one after the other.

Galcanezumab (Emgality)

As with Ajovy, Emgality

Emgality is available as monthly 120-mg injections with a starting dose of 240 mg.

Eptinezumab (Vyepti)

Vyepti

All the other mAbs for migraine are subcutaneous, meaning that a person injects this just under the skin. However, Vyepti is the only CGRP antagonist doctors deliver as an intravenous (IV) infusion directly into the blood vessels. This may mean that it acts quickly and the body absorbs all of it.

Physicians will often recommend 100 mg of Vyepti every 3 months. Certain people might benefit from a triple dose to last the same length of time.

Gepants are available as oral pills or dissolvable tablets, instead of injections such as mAbs. They are also known as small molecule CGRP receptor antagonists.

As this name suggests, gepants bind to CGRP receptors and block their effect. Additionally, unlike some other medications, they do not constrict blood vessels but prevent them from dilating. This makes them a safer alternative for people with heart or cardiovascular disease.

There are three gepants available in the United States, with more in development. The current ones are:

According to a

CGRP also

In a

Evidence notes the most common side effects of gepants include:

Treatment for migraine revolves around reducing how often attacks happen and the severity of pain when they do.

Acute treatments for migraine

The following medication

  • pain relief medications, such as nonsteroidal anti-inflammatory drugs and acetaminophen
  • antisickness medications (antiemetics), including metoclopramide and domperidone
  • triptans, which are prescription medications that can help both moderate to severe pain and sickness during a migraine episode
  • ergot derivative drugs, which reduce how many pain messages travel along nerve fibers and have the greatest effect early on in a migraine attack
  • ditans, such as lasmiditan, which can treat moderate to severe migraines, but can cause drowsiness

Preventing migraine episodes

Reducing the frequency of migraine attacks may involve CGRP mAbs and gepants, as well as:

  • anticonvulsant medications
  • antidepressant medications
  • beta-blockers

Lifestyle measures for reducing migraine episodes

Treatment may be necessary for severe migraine. However, taking measures at home can help people with migraine maintain comfort during attacks. These might involve:

  • lying down in a quiet, dark room to take a nap
  • placing a cool cloth or ice pack on the forehead
  • consuming regular fluids, especially if the individual is also vomiting

A person can help reduce the number of attacks by:

  • exercising regularly
  • avoiding foods and drinks that trigger migraine attacks
  • eating regularly scheduled meals
  • drinking enough water
  • quitting certain medications if they trigger migraine
  • setting up a regular sleep schedule
  • practicing weight management, as obesity increases the risk of developing chronic daily headaches

Optum Perks is owned by RVO Health. By clicking on this link, we may receive a commission. Learn more.

CGRP is a protein that has links to several processes in the body. One of these processes causes pain sensations in people with migraine. The first preventive migraine medications — CGRP mAbs — are one of two drugs that target CGRP or its receptors in the brain.

These injectable or infusible medications are multiple synthetic copies of immune system proteins. They block the activity of CGRP by binding to the protein or the receptor. CGRP mAbs may cause side effects given CGRP’s role in other body functions, such as heart health or food movements through the gut.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What does "targeted" therapy mean?

Calcitonin gene-related peptide (CGRP) is a molecule that is synthesized in neurons (nerve cells in the brain and spinal cord). It has been implicated in different pain processes, including migraine, and functions as a vasodilator — that is, it relaxes blood vessels. Once scientists identified this target molecule, they began trying to develop ways to stop it from being activated at the start of migraines, as a kind of abortive treatment. An agonist makes a molecule work more efficiently, and an antagonist blocks or reduces the molecule's effect. The CGRP antagonist did work to decrease migraine pain based on certain measures, but there were some serious side effects including liver toxicity. Back to the drawing board.

Source: www.health.harvard.edu ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →